Bioclinical markers in breast cancer: updates and perspectives (original) (raw)
Quantitative Real-Time Reverse Transcription PCR Assay for Urokinase Plasminogen Activator, Plasminogen Activator Inhibitor Type 1, and Tissue Metalloproteinase Inhibitor Type 1 Gene Expressions in Primary Breast Cancer
Carlos Vazquez
View PDFchevron_right
Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 mRNA Assessment in Breast Cancer by Means of NASBA: Correlation With Protein Expression
Alejandro Cuellar
American Journal of Clinical Pathology, 2007
View PDFchevron_right
Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 mRNA Assessment in Breast Cancer by Means of NASBA
Alejandro Bravo Cuellar
American Journal of Clinical Pathology, 2007
View PDFchevron_right
Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer
Mads Holten-Andersen
Molecular & Cellular Proteomics, 2003
View PDFchevron_right
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
Peter Andreasen
Cancer research, 1990
View PDFchevron_right
Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance
James Wittliff
Journal of Clinical Laboratory Analysis, 2012
View PDFchevron_right
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
Karin Milde-langosch, T. Karn
OncoTargets and Therapy, 2014
View PDFchevron_right
Urokinase-Plasminogen Activator, a New and Independent Prognostic Marker in Breast Cancer1
Peter Andreasen
2000
View PDFchevron_right
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
Rajko Kavalar
Radiology and Oncology, 2014
View PDFchevron_right
Urokinase-Type Plasminogen Activator System in Breast Cancer
Michael Duffy
Cancer Research, 2004
View PDFchevron_right
Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas
James Wittliff
Journal of Clinical Laboratory Analysis
View PDFchevron_right
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine
Adel Gouri
Biomarker Insights, 2016
View PDFchevron_right
Prognostic molecular markers in early breast cancer
Francisco Esteva
Breast cancer research : BCR, 2004
View PDFchevron_right
Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients
Kurt Ulm, Marinus Blankenstein
JNCI Journal of the National Cancer Institute, 2002
View PDFchevron_right
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer
Marion Kiechle, Manfred Schmitt
Clinical breast cancer, 2004
View PDFchevron_right
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies
Michael Duffy
Breast cancer research : BCR, 2014
View PDFchevron_right
Urokinase plasminogen activator: a prognostic marker in breast cancer including …
Enda McDermott
Clinical …, 1998
View PDFchevron_right
Increased Expression of Urokinase-Type Plasminogen Activator mRNA Determines Adverse Prognosis in ErbB2-Positive Primary Breast Cancer
Ross Stephens
Journal of Clinical Oncology, 2006
View PDFchevron_right
Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer
Gunter Von Minckwitz
Breast Care, 2008
View PDFchevron_right
Biomarkers in breast cancer
Svetislav Vrbic
Jugoslovenska medicinska biohemija, 2006
View PDFchevron_right
Measurement of the Uncomplexed Fraction of Tissue Inhibitor of Metalloproteinases-1 in the Prognostic Evaluation of Primary Breast Cancer Patients
Anne-Sofie Schrohl
Molecular & Cellular Proteomics, 2005
View PDFchevron_right
Plasminogen activator inhibitor type 2 in breast cancer
Niall OHiggins
British journal of cancer, 1997
View PDFchevron_right
Prognostic significance of the urokinase type plasminogen activator (u-PA) system in node-negative breast cancer
kim myung jin
Breast Cancer, 1999
View PDFchevron_right
Prognostic Significance of Tissue Inhibitor of Metalloproteinase-1 in Breast Cancer
John Mackey
International Journal of Breast Cancer, 2012
View PDFchevron_right
Tumor markers in breast cancer--evaluation of their clinical usefulness
Katarina Antunac, Petar Ozretić, Lidija Beketic-Oreskovic
Collegium antropologicum, 2011
View PDFchevron_right
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: Comparison to antigen quantification by ELISA
Marion Kiechle, Manfred Schmitt
International Journal of Molecular Medicine, 2008
View PDFchevron_right
Metalloproteinases: promising tumor markers for breast cancer management
Lilit Garibyan
Current Surgery, 2004
View PDFchevron_right
Plasminogen Activator Inhibitor Type 1 is the Most Significant of the Usual Tissue Prognostic Factors in Node-Negative Breast Ductal Adenocarcinoma Independent of Urokinase-Type Plasminogen Activator
Jean Rony Andre
Clinical Breast Cancer, 2008
View PDFchevron_right
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
Christian Rosenquist
Cancer research, 1993
View PDFchevron_right